Genomic Therapy Offers Hope in Treatment of Lung Cancer

04:41 EDT 17 Aug 2017 | Genetic Engineering News

Norton Thoracic Institute researchers believe they have discovered a new approach to treating an aggressive and difficult to treat type of lung cancer. They published their study ("WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non–Small Cell Lung Cancer") in  Cancer Research . The team found that lung cancer patients whose tumors harbor specific genomic mutations are more likely to benefit from a novel drug, AZD1775, currently in clinical trials. "The tumor suppressor serine/threonine kinase 11 ( LKB1/STK11 ) is one of the most frequently mutated genes in non–small cell lung cancer (NSCLC) and is commonly comutated with oncogenic  KRAS  mutations. We investigated the preclinical effects of AZD1775 in the context of  KRAS / LKB1  in NSCLC," write the investigators. "Using NSCLC cell lines, we found that AZD1775 alone and in combination with DNA-damaging agents (e.g., cisplatin and radiation) decreased tumor cell viability in  LKB1 -deficient NSCLC cells...In a genetically engineered ...

Original Article: Genomic Therapy Offers Hope in Treatment of Lung Cancer


More From BioPortfolio on "Genomic Therapy Offers Hope in Treatment of Lung Cancer"

Quick Search


Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...